clinical trial · NCT05220410
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Sheppard Pratt Health System·phase2·completed·n = 20
Treatment Resistant DepressionSuicidal IdeationPsilocybin
brief summary
This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation
started
Mar 28, 2022
primary completion
May 12, 2025
completion
May 12, 2025
last updated
Dec 24, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol